EZETIMIBE/SIMVASTATIN MSD 10 mg/40 mg ezetimibe 10 mg and simvastatin 40 mg tablet blister pack

Χώρα: Αυστραλία

Γλώσσα: Αγγλικά

Πηγή: Department of Health (Therapeutic Goods Administration)

Δραστική ουσία:

simvastatin, Quantity: 40 mg; ezetimibe, Quantity: 10 mg

Διαθέσιμο από:

ORGANON PHARMA PTY LTD

INN (Διεθνής Όνομα):

Ezetimibe,Simvastatin

Φαρμακοτεχνική μορφή:

Tablet, uncoated

Σύνθεση:

Excipient Ingredients: magnesium stearate; butylated hydroxyanisole; citric acid monohydrate; microcrystalline cellulose; croscarmellose sodium; propyl gallate; lactose monohydrate; hypromellose

Οδός χορήγησης:

Oral

Μονάδες σε πακέτο:

5 tablets, 30 tablets, 10 tablets

Τρόπος διάθεσης:

(S4) Prescription Only Medicine

Θεραπευτικές ενδείξεις:

Adults (greater than or equal to 18 years),Prevention of cardiovascular disease,EZETIMIBE/SIMVASTATIN MSD is indicated in patients with coronary heart disease (CHD) and a history of acute coronary syndrome (ACS) taking their maximum tolerated dose of simvastatin and in need of additional lowering of LDL-C in the expectation of a modest further reduction in the risk of cardiovascular events following at least one year of therapy (see Section 5.1 Pharmacodynamic Properties, Clinical trials).,Primary hypercholesterolaemia,EZETIMIBE/SIMVASTATIN MSD is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia or mixed hyperlipidaemia where use of a combination product is appropriate:,- Patients not appropriately controlled with a statin or ezetimibe alone.,- Patients already treated with a statin and ezetimibe.,Homozygous Familial Hypercholesterolaemia (HoFH),EZETIMIBE/SIMVASTATIN MSD is indicated in patients with HoFH. Patients may also receive adjunctive treatments (e.g., LDL apheresis).,Children and adolescents 10-17 years,(pubertal status: boys Tanner Stage II and above and girls who are at least one year post-menarche) Heterozygous Familial Hypercholesterolaemia (HeFH),EZETIMIBE/SIMVASTATIN MSD is indicated as adjunctive therapy to diet in adolescent patients (10-17 years old) with heterozygous familial hypercholesterolaemia where use of a combination product is appropriate:,- Patients not appropriately controlled with a statin or ezetimibe alone.,- Patients already treated with a statin and ezetimibe.,Homozygous Familial Hypercholesterolaemia (HoFH),EZETIMIBE/SIMVASTATIN MSD is indicated in adolescent patients (10-17 years old) with HoFH. Patients may also receive adjunctive treatments (e.g., LDL apheresis).

Περίληψη προϊόντος:

Visual Identification: White to off-white, capsule shaped, biconvex compressed tablet with "313" marked on the tablet; Container Type: Blister Pack; Container Material: PVC/PCTFE (Aclar)/Al; Container Life Time: 18 Months; Container Temperature: Store below 25 degrees Celsius

Καθεστώς αδειοδότησης:

Licence status A

Ημερομηνία της άδειας:

2015-11-25